Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2
Authors:
Open Access
- 18 December 2023
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (52)
Abstract
Currently, monoclonal antibodies (MAbs) targeting the SARS-CoV-2 receptor binding domain (RBD) of spike (S) protein are classified into seven classes based on their binding epitopes. However, most of these antibodies are seriously impaired by SARS-CoV-2 Omicron and its subvariants, especially the recent BQ.1.1, XBB and its derivatives. Identification of broadly neutralizing MAbs against currently circulating variants is imperative. In this study, we identified a “breathing” cryptic epitope in the S protein, named as RBD-8. Two human MAbs, BIOLS56 and IMCAS74, were isolated recognizing this epitope with broad neutralization abilities against tested sarbecoviruses, including SARS-CoV, pangolin-origin coronaviruses, and all the SARS-CoV-2 variants tested (Omicron BA.4/BA.5, BQ.1.1, and XBB subvariants). Searching through the literature, some more RBD-8 MAbs were defined. More importantly, BIOLS56 rescues the immune-evaded antibody, RBD-5 MAb IMCAS-L4.65, by making a bispecific MAb, to neutralize BQ.1 and BQ.1.1, thereby producing an MAb to cover all the currently circulating Omicron subvariants. Structural analysis reveals that the neutralization effect of RBD-8 antibodies depends on the extent of epitope exposure, which is affected by the angle of antibody binding and the number of up-RBDs induced by angiotensin-converting enzyme 2 binding. This cryptic epitope which recognizes non- receptor binding motif (non-RBM) provides guidance for the development of universal therapeutic antibodies and vaccines against COVID-19.Keywords
Funding Information
- Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010202)
- Beijing Natural Science Foundation (M23009)
- The National Natural Science Foundation of China (82022042)
- The National Natural Science Foundation of China (32090014)
- The National Natural Science Foundation of China (31872745)
- the National Key R&D Program of China (2020YFA0907104)
This publication has 47 references indexed in Scilit:
- “Breathing” Hemagglutinin Reveals Cryptic Epitopes for Universal Influenza Vaccine DesignCell, 2019
- Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virusNature Microbiology, 2019
- MolProbity: More and better reference data for improved all‐atom structure validationProtein Science, 2017
- Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyondTrends in Microbiology, 2015
- Bispecific Antibodies: Developments and Current Perspectives2011
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- PHENIX: building new software for automated crystallographic structure determinationActa Crystallographica Section D Structural Biology, 2002
- Processing of X-ray diffraction data collected in oscillation mode.1997
- [20] Processing of X-ray diffraction data collected in oscillation mode1997